Adenosarcoma of the uterus

A rare uterine neoplasm that originates in the ENDOMETRIUM and contains a mixture of benign and malignant components. It is most common in post-menopausal women, in those with hyperestrogenemia (high blood estrogen levels), or who have undergone chemotherapy or radiotherapy.

Also Known As:

Networked: 35 relevant articles (2 outcomes, 7 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Adenosarcoma
3.	Neoplasm Metastasis (Metastasis)
4.	Carcinoma (Carcinomatosis)
5.	Endometrioid Carcinoma

Experts

1.	Jones, Robin L: 2 articles (02/2014 - 06/2013)
2.	Pollack, Seth M: 2 articles (02/2014 - 06/2013)
3.	Amant, Frederic: 2 articles (12/2004 - 06/2004)
4.	Moerman, Philippe: 2 articles (12/2004 - 06/2004)
5.	Verbist, Lieve: 2 articles (12/2004 - 06/2004)
6.	Vergote, Ignace: 2 articles (12/2004 - 06/2004)
7.	Ayhan, Ali: 1 article (04/2022)
8.	Haberal Reyhan, A Nihan: 1 article (04/2022)
9.	Ok Atılgan, Alev: 1 article (04/2022)
10.	Yılmaz Akçay, Eda: 1 article (04/2022)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Adenosarcoma of the uterus:

1.	TrabectedinIBA 06/01/2013 - "This study assessed the safety and efficacy of trabectedin in patients with recurrent/metastatic uterine adenosarcoma with sarcomatous overgrowth. " 06/01/2013 - "Trabectedin is well tolerated and has clinical activity in recurrent/metastatic uterine adenosarcoma." 06/01/2013 - "Three patients with recurrent/metastatic uterine adenosarcoma treated with trabectedin were identified. " 06/01/2013 - "Clinical benefit of trabectedin in uterine adenosarcoma."
2.	Proteins (Proteins, Gene)FDA Link 06/01/2023 - "PD-L1 and PD-L2, and tumor protein p53 (p53) were examined in 20 uterine adenosarcoma cases, and tumor-infiltrating lymphocytes and tumor-associated macrophages were counted in tumor tissue using immunohistochemistry. " 03/01/2023 - "In this study, 111 separate gynecologic tumors were studied for SEC14L1 protein expression, including: uterine adenosarcoma, ovarian clear cell carcinoma, endometrial stromal sarcoma, endometrioid carcinoma of the uterus, high-grade serous carcinoma, ovarian endometrioid carcinoma, uterine leiomyosarcoma, low-grade serous carcinoma, uterine carcinosarcoma, and uterine serous carcinoma (USC). " 01/01/2023 - "In this study, DNA mismatch repair proteins, p16, cyclin D1, ER, PR, and CD10 were examined in uterine adenosarcoma cases using immunohistochemistry. " 01/01/2023 - "Microsatellite Instability Status and the Expression of p16 and Cyclin D1 Proteins in Uterine Adenosarcoma and Their Clinicopathological Significance."
3.	Cyclin D1IBA 01/01/2023 - "In this study, DNA mismatch repair proteins, p16, cyclin D1, ER, PR, and CD10 were examined in uterine adenosarcoma cases using immunohistochemistry. " 01/01/2023 - "Microsatellite Instability Status and the Expression of p16 and Cyclin D1 Proteins in Uterine Adenosarcoma and Their Clinicopathological Significance."
4.	CyclinsIBA 01/01/2023 - "Additionally, the current study showed that cyclin D1-positive tumors had high recurrence rates; however, no significant relationships were found between MSI and DFS or OS in patients with uterine adenosarcoma. "
5.	Progesterone Receptors (Progesterone Receptor)IBA 06/01/2004 - "Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcoma." 06/01/2004 - "Given the paucity of data regarding hormone dependency, it was the purpose of this study to screen for the presence of estrogen and progesterone receptors in uterine adenosarcoma (UAS). "
6.	Hormones (Hormone)IBA 06/01/2004 - "Given the paucity of data regarding hormone dependency, it was the purpose of this study to screen for the presence of estrogen and progesterone receptors in uterine adenosarcoma (UAS). "
7.	Estrogens (Estrogen)FDA Link 06/01/2004 - "Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcoma." 06/01/2004 - "Given the paucity of data regarding hormone dependency, it was the purpose of this study to screen for the presence of estrogen and progesterone receptors in uterine adenosarcoma (UAS). "
8.	TamoxifenFDA LinkGeneric 12/01/2003 - "Sonography and MRI of tamoxifen-associated müllerian adenosarcoma of the uterus." 09/01/2000 - "Mullerian adenosarcoma of the uterus associated with tamoxifen therapy." 01/01/2000 - "Müllerian adenosarcoma of the uterus in association with tamoxifen therapy." 12/01/2015 - "Mullerian adenosarcoma of the uterus associated with tamoxifen treatment for breast cancer." 10/19/2012 - "Uterine adenosarcoma in a patient with history of breast cancer and long-term tamoxifen consumption."
9.	IfosfamideFDA LinkGeneric 01/01/2018 - "Among these patients, we provided a detailed description of the medical history of a 49-year-old woman with advanced uterine adenosarcoma with sarcomatous overgrowth who presented a brilliant radiologic and pathologic response after 3 cycles of epirubicin and ifosfamide, ultimately achieving an extraordinary long-term outcome through an integrated surgical and medical approach. " 01/01/2017 - "These results suggest that surgery is an important treatment modality for recurrent or metastatic uterine adenosarcoma, and the most effective chemotherapeutics are doxorubicin/ifosfamide and gemcitabine/docetaxel."
10.	Neprilysin (Neutral Endopeptidase)IBA 11/01/2004 - "Immunohistochemical expression of CD10 antigen in uterine adenosarcoma."

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 04/01/2023 - "ATM mutation in aggressive uterine adenosarcoma in which systemic chemotherapies had remarkable effects." 10/01/2023 - "A combination of chemotherapy and radiotherapy may be a promising treatment option for uterine adenosarcoma with postoperative residual disease." 01/01/2017 - "This study retrospectively evaluated overall survival (OS) by treatment of recurrent or metastatic uterine adenosarcoma including surgery, radiation, chemotherapy, and hormonal therapy and evaluated OS and progression-free survival (PFS) after 1st line systemic chemotherapy. " 09/23/2022 - "Age, marital status, tumor size, T stage, grade, and chemotherapy are independent prognostic factors of uterine adenosarcoma. " 06/01/2013 - "Uterine adenosarcoma is an extremely rare uterine malignancy, and the utility of chemotherapy in this disease is not well defined. "
2.	Radiotherapy 01/01/2019 - "Peritoneal lavage cytology and radiotherapy did not improve prognosis of uterine adenosarcoma." 01/01/2019 - "Peritoneal lavage cytology and radiotherapy were risk factors affecting PFS and peritoneal lavage cytology for OS in patients with uterine adenosarcoma. " 10/01/2023 - "A combination of chemotherapy and radiotherapy may be a promising treatment option for uterine adenosarcoma with postoperative residual disease."
3.	Therapeutics 12/01/2014 - "We aimed to clarify the impact of adjuvant therapy in patients with uterine adenosarcoma and identify risk factors for recurrence and death. " 02/01/2014 - "Systemic therapy in advanced uterine adenosarcoma with sarcomatous overgrowth." 11/01/2001 - "A 25-year-old nulligravida was diagnosed with a uterine adenosarcoma and the question of conservative surgical therapy arose. " 01/01/2017 - "This study retrospectively evaluated overall survival (OS) by treatment of recurrent or metastatic uterine adenosarcoma including surgery, radiation, chemotherapy, and hormonal therapy and evaluated OS and progression-free survival (PFS) after 1st line systemic chemotherapy. " 08/01/2018 - "This study showed the clinicopathologic features of Japanese patients with uterine adenosarcoma and suggested potential solutions for improving prognosis including early treatment based on a timely diagnosis, the development of effective adjuvant therapy for patients at high risk of recurrence, and optimal follow-up focusing on late recurrence and lung metastasis."
4.	Lymph Node Excision (Lymph Node Dissection) 09/23/2022 - "The objective for the study was to analysis the epidemiology of adenosarcoma, and independent prognostic factors and impact of lymph node dissection (LND) of uterine adenosarcoma. " 09/23/2022 - "Epidemiology of adenosarcoma and the inverse probability of treatment weighting (IPTW) adjusted survival analysis of lymph node dissection in uterine adenosarcoma."
5.	Hysterectomy 12/01/2011 - "Total abdominal hysterectomy with bilateral salpingo-oopherectomy was performed and the histopathology report confirmed the diagnosis of uterine adenosarcoma with ovarian sex cord like-differentiation. " 05/18/2009 - "Finally, a total abdominal hysterectomy was performed because of atypical cells and suspected uterine adenosarcoma. " 10/01/2023 - "In patients with uterine adenosarcoma, a total abdominal hysterectomy (TAH) with bilateral salpingo-oophorectomy (BSO) is typically recommended as an initial treatment. " 10/01/2023 - "The uterine adenosarcoma with postoperative residual in a woman treated by total abdominal hysterectomy/bilateral salpingo-oophorectomy: A case report and review of literature." 01/01/1992 - "We report on the clinical and pathologic findings in 31 cases of adenosarcoma of the uterus subjected to hysterectomy and staging laparotomy. "